Anti-PRDM6 / PR domain zinc finger protein 6

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. The PRDM6 antibody targets PR domain zinc finger protein 6, a transcriptional repressor encoded by the PRDM6 gene. This protein is a member of the PRDM family, which combines a PR (PRDI-BF1 and RIZ1 homology) domain with multiple C2H2-type zinc fingers to regulate chromatin structure and gene expression. PR domain zinc finger protein 6 acts as an epigenetic modulator that influences vascular smooth muscle cell (VSMC) differentiation, proliferation, and contractility. The PRDM6 antibody allows precise detection of this transcriptional regulator, supporting studies into vascular development, remodeling, and disease.PR domain zinc finger protein 6 functions as a transcriptional repressor by recruiting histone methyltransferases and corepressor complexes, leading to trimethylation of histone H3 on lysine 9 (H3K9me3) and gene silencing. It is preferentially expressed in smooth muscle?derived lineages where it regulates genes controlling contractile protein synthesis and cell fate. The PRDM6 antibody provides a reliable means to monitor expression changes during phenotypic switching of VSMCs between contractile and proliferative states, a process central to vascular injury response and atherosclerosis.Loss-of-function mutations in PRDM6 have been associated with patent ductus arteriosus (PDA) and other congenital heart defects. These variants impair transcriptional repression of target genes involved in vascular maturation. The PRDM6 antibody facilitates investigation into such pathogenic mechanisms by allowing detection of wild-type and mutant protein forms. In developmental studies, PR domain zinc finger protein 6 has been shown to coordinate the balance between smooth muscle proliferation and differentiation during embryogenesis, acting downstream of BMP and TGF-beta signaling pathways.Beyond cardiovascular biology, PR domain zinc finger protein 6 has been implicated in oncogenesis through its role in epigenetic gene silencing. Aberrant PRDM6 expression or methylation patterns have been observed in multiple cancer types, suggesting that dysregulation of this transcriptional repressor contributes to uncontrolled cell growth. The PRDM6 antibody enables detailed exploration of its epigenetic regulatory activity in cancer and stem cell systems, providing insight into how histone modification and chromatin structure impact disease progression.The PRDM6 antibody performs effectively in western blotting, immunofluorescence, and immunohistochemistry, showing predominant nuclear localization consistent with its transcriptional role. NSJ Bioreagents provides this antibody with validated specificity and consistency for use in molecular biology, vascular research, and epigenetic studies. By facilitating detailed analysis of PR domain zinc finger protein 6 expression and function, the PRDM6 antibody supports ongoing research into vascular development, gene regulation, and the epigenetic mechanisms that govern smooth muscle cell behavior.